Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v24-EN Version v1-EN
Language English English
Date Updated 2022-10-18 2021-07-08
Drug Identification Number 02286831 02286831
Brand name TEVA-SUMATRIPTAN DF TEVA-SUMATRIPTAN DF
Common or Proper name TEVA-SUMATRIPTAN DF 100MG TAB P/P 6 TEVA-SUMATRIPTAN DF 100MG TAB P/P 6
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients SUMATRIPTAN SUMATRIPTAN
Strength(s) 100MG 100MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size PP6 6
ATC code N02CC N02CC
ATC description ANTIMIGRAINE PREPARATIONS ANTIMIGRAINE PREPARATIONS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2021-07-08 2021-07-08
Estimated end date 2022-10-10 2021-08-31
Actual end date 2022-10-17
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments